Health innovations that matter

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncology and hepatology.

Most recent

May 07, 2021

Virtual Annual General Meeting Guidelines

May 07, 2021

Virtual Annual Meeting of Shareholders

April 21, 2021

Bloom Burton & Co. Healthcare Investor Conference

Making a difference

Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing niche therapeutic needs.

Our values


The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.


There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.


We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our commercialized products

Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is approved in the United States while EGRIFTA® is available only in Canada.